% | $
Quotes you view appear here for quick access.

Amarantus Bioscience Holdings, Inc Message Board

  • solantey Apr 17, 2013 11:23 AM Flag

    Bio-Tech Analyst Jason Napadano Values the Company At .24 Currently

    From today's Seeking Alpha article:

    In a previous article on Amarantus BioScience Holdings, Inc., I concluded that MANF was worth an estimated $42 million in value over at the Amarantus Therapeutics division given all the available scientific data. As such, I see the entire company worth an estimated $92 million. Given an estimated ~390 million share count, that equates to a target price of $0.24 per share. I expect the value of Amarantus to rise as investors become more familiar with LymPro and the company begins to generate the necessary data for a CLIA filing.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.350.00(-0.28%)Nov 25 3:57 PMEST